Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Ovarian Neoplasms 1Neoplasms, Second Primary 1NSCLC 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Kidney Neoplasms 1Gastro Intestinal Stromal Tumor 1Endometrial Neoplasms 1Congenital Abnormalities 1Asymptomatic Brain Metastases 1

Interventions

pembrolizumab 34Cisplatin 30Brachytherapy 16Paclitaxel 15Carboplatin 15Bevacizumab 15Radiotherapy 14Blood Specimen Collection 13Specimen Handling 12Magnetic Resonance Spectroscopy 11Colposcopy 11Nivolumab 10Drug Therapy 10atezolizumab 8Human Papillomavirus DNA Tests 8Gemcitabine 8lenvatinib 7Radiation 6Platinum 6Biopsy 6toripalimab 5cemiplimab 5Surveys and Questionnaires 5Standard of Care 5Radiotherapy, Intensity-Modulated 5Practice Guidelines as Topic 5Patient Navigation 5Methods 5Fulvestrant 5Fluorodeoxyglucose F18 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Tyrosine Kinase Inhibitors × 1 year × Clear all
NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Sun Yat-sen University

Phase 2 Active not recruiting
30 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡